These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26235262)

  • 1. Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report.
    Leo L; Caputo F; Sarno AD; Garofano T; Andreozzi F; Massaro MG; Montesarchio V
    Future Oncol; 2015; 11(15 Suppl):27-30. PubMed ID: 26235262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eribulin rapidly reduces the aggressiveness of second primary breast cancer: a case report.
    Falco I; Stragliotto S
    Future Oncol; 2017 Apr; 13(11s):51-54. PubMed ID: 28481187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.
    Fabi A; Moscetti L; Ciccarese M; Caramanti M; Salesi N; La Verde N; Russillo M; Generali D; Scandurra G; Vari S; Pacetti U; Cognetti F; Giannarelli D
    Future Oncol; 2015; 11(3):431-8. PubMed ID: 25675124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.
    Martella F; Bacci C; Giordano C; Montagnani F; Gelain E; Rabatti L; Fioretto L
    Future Oncol; 2015; 11(15 Suppl):31-6. PubMed ID: 26235263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinal metastasis regression with eribulin in a heavily pretreated breast cancer patient.
    Gubbiotti M; Pistilli B; Tudini M; Benedetti G; Galizia E; Rusiello M; Latini L
    Future Oncol; 2015; 11(15 Suppl):17-22. PubMed ID: 26235260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.
    Prestifilippo A; Grippaldi D; Blanco G; Memeo L; Puliafito I; Giuffrida D
    Future Oncol; 2017 Apr; 13(11s):5-10. PubMed ID: 28481186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eribulin long-term response and rechallenge: report of two clinical cases.
    Barbieri E; Rubino D; Hakim R; Fini A; Lenzi M; Zamagni C
    Future Oncol; 2017 Apr; 13(11s):35-43. PubMed ID: 28481188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital.
    Poletti P; Ghilardi V; Livraghi L; Milesi L; Rota Caremoli E; Tondini C
    Future Oncol; 2014 Feb; 10(2):233-9. PubMed ID: 24490609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series.
    Morritti M; Iodice G; Melaccio A; D'Onofrio L; Bergnolo P; Boglione A; Comandone A; Molinaro P; Garigliano D
    Future Oncol; 2017 Apr; 13(11s):25-33. PubMed ID: 28481183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eribulin as an effective monotherapy in a chemo-pretreated woman with metastatic breast cancer: a case report.
    Caputo R; Cianniello D; De Laurentiis M
    Future Oncol; 2017 Apr; 13(11s):45-50. PubMed ID: 28481184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit of eribulin in a patient with HER2(+) breast cancer who progressed after trastuzumab and lapatinib: a case report.
    Casanova C; Verlicchi A; Mazza V; Dazzi C
    Future Oncol; 2015; 11(15 Suppl):9-15. PubMed ID: 26235259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
    Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
    Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients.
    Quaquarini E; Sottotetti F; D'Ambrosio D; Malovini A; Morganti S; Marinello A; Pavesi L; Frascaroli M
    Future Oncol; 2017 Apr; 13(11s):11-23. PubMed ID: 28481185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long response to eribulin in breast cancer: a case report.
    Borgonovo K; Petrelli F; Cabiddu M; Ghilardi M; Coinu A; Seghezzi S; Barni S
    Future Oncol; 2015; 11(15 Suppl):3-8. PubMed ID: 26235258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer.
    O'Shaughnessy J; Kaklamani V; Kalinsky K
    Future Oncol; 2019 May; 15(14):1641-1653. PubMed ID: 30892083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
    Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
    J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient.
    Miano ST; Francini E; Petrioli R; Francini G
    Future Oncol; 2020 Jan; 16(1s):33-38. PubMed ID: 31975628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'.
    Lorusso V; Cinieri S; Latorre A; Porcu L; Del Mastro L; Puglisi F; Barni S
    Future Oncol; 2017 May; 13(11):971-978. PubMed ID: 28326833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of skeletal and bone marrow metastases from breast cancer treated with eribulin mesylate.
    Pashaj E; Cortesi L; Proietto M; Bonacorsi G; Liardo E; Federico M
    Future Oncol; 2013 Oct; 9(10):1437-42. PubMed ID: 24106895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
    J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.